NCT00803907

Imiquimod 5% Cream for the Treatment of Periocular Basal Cell Carcinoma

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: University of Sao Paulo · Academic / Other
• Sex: All
• Age: 18 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

This study aimed to prove the efficacy and safety of the use of imiquimod 5% cream in the periorbital region.

Detailed description

This is a prospective study including patients presenting in aggregate primary lesions affected by nodular BCC of the eyelid (all subjects were submitted to incisional biopsy at 2 mm punch) at the commencement of this study. All were submitted to a local treatment with Imiquimod 5% cream (Aldara ®), once daily, 5 days per week for 8-16 weeks (average). All subjects were submitted to a new incisional biopsy at 2 mm punch, after 12 weeks of treatment, and all of them were monitored monthly up to now.If positive biopsy (residue tumor) cases will managed with surgery.

Conditions

• Carcinoma, Basal Cell

Interventions

Type	Name	Description
DRUG	Imiquimod 5% cream	Imiquimod 5% cream (Aldara ®), once daily, 5 days per week for 8-16 weeks (average)

Timeline

• Start date: 2008-12-01
• Primary completion: 2012-09-01
• Completion: 2013-02-01
• First posted: 2008-12-08
• Last updated: 2012-06-13

Locations

1 site across 1 country: Brazil